Kombineret analyse af begge forsøg viste, at 83% af patienterne, som fik fulvestrant, progredierede i forhold til 85% af patienterne, der fik anastrozol.
Combined analysis of both trials showed that 83% of patients who received fulvestrant progressed, compared with 85% of patients who received anastrozole.